{"id":"NCT03875729","sponsor":"Provention Bio, Inc.","briefTitle":"Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab","officialTitle":"Phase 3 Randomized Double-Blind Multinational Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab, a Humanized Fc Receptor (FcR) Non-Binding Anti-cluster of Differentiation 3 (CD3) Monoclonal Antibody, in Children and Adolescents With Newly Diagnosed Type 1 Diabetes","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-04-05","primaryCompletion":"2023-05-01","completion":"2023-05-01","firstPosted":"2019-03-15","resultsPosted":"2024-04-24","lastUpdate":"2024-04-24"},"enrollment":328,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 1 Diabetes Mellitus"],"interventions":[{"type":"BIOLOGICAL","name":"teplizumab","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"Teplizumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine whether teplizumab slows the loss of β cells and preserves β cell function in children and adolescent 8-17 years old who have been diagnosed with T1D in the previous 6 weeks..\n\nSubjects will receive two courses of either teplizumab or placebo treatment 6 months apart.","primaryOutcome":{"measure":"Change in C-peptide ln(AUC+1) Standardized by Duration of the Mixed Meal Tolerance Test (MMTT)","timeFrame":"Baseline to Week 78","effectByArm":[{"arm":"Placebo","deltaMin":-0.2112,"sd":null},{"arm":"Teplizumab","deltaMin":-0.0859,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"8 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":62,"countries":["United States","Belgium","Canada","Czechia","France","Germany","Hungary","Poland","United Kingdom"]},"refs":{"pmids":["37861217","39735417","37158990"],"seeAlso":["http://pubmed.ncbi.nlm.nih.gov/37861217/"]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":111},"commonTop":["Hypoglycaemia","Headache","Nausea","Rash","Vomiting"]}}